Novo Nordisk A/S’s Rybelsus diabetes pill, a tablet version of Ozempic, reduced the risk of heart attacks and strokes in a large study that may drive broader use of the drug.

Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to ...

Novo Nordisk’s oral semaglutide lowered the risk of certain heart events in a late-phase study in people with type 2 diabetes ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding ...

Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...

Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular ...

Here's all you need to know about Ozempic that Karan Johar is said to have used for fast weight loss. What are the benefits ...

The State’s failure to alleviate shortages of weight-loss drug Ozempic demonstrates an apathy towards obesity patients, a ...